RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 22.78 Thousand USD | -89.09% |
| 2021 | 208.73 Thousand USD | 145.32% |
| 2020 | 85.08 Thousand USD | 87.71% |
| 2019 | 45.32 Thousand USD | -63.5% |
| 2018 | 124.19 Thousand USD | -36.24% |
| 2017 | 194.77 Thousand USD | -16.71% |
| 2016 | 233.84 Thousand USD | 60.34% |
| 2015 | 145.84 Thousand USD | -63.57% |
| 2014 | 400.3 Thousand USD | 671.98% |
| 2013 | 51.85 Thousand USD | -73.91% |
| 2012 | 198.72 Thousand USD | -89.08% |
| 2011 | 1.82 Million USD | -48.96% |
| 2010 | 3.56 Million USD | 405.29% |
| 2009 | 705.97 Thousand USD | -86.3% |
| 2008 | 5.15 Million USD | -72.04% |
| 2007 | 18.42 Million USD | 76.61% |
| 2006 | 10.43 Million USD | -41.99% |
| 2005 | 17.98 Million USD | -39.86% |
| 2004 | 29.91 Million USD | 1272.68% |
| 2003 | 2.17 Million USD | -26.9% |
| 2002 | 2.98 Million USD | -46.2% |
| 2001 | 5.54 Million USD | 58.84% |
| 2000 | 3.48 Million USD | 125.18% |
| 1999 | 1.54 Million USD | -46.12% |
| 1998 | 2.87 Million USD | -65.5% |
| 1997 | 8.33 Million USD | 66.2% |
| 1996 | 5.01 Million USD | 2.32% |
| 1995 | 4.9 Million USD | -52.88% |
| 1994 | 10.4 Million USD | 447.37% |
| 1993 | 1.9 Million USD | -38.71% |
| 1992 | 3.1 Million USD | -6.06% |
| 1991 | 3.3 Million USD | -15.38% |
| 1990 | 3.9 Million USD | 178.57% |
| 1989 | 1.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 95.88 Thousand USD | 320.91% |
| 2023 Q2 | 141.27 Thousand USD | 47.34% |
| 2023 Q3 | 108.66 Thousand USD | -23.08% |
| 2022 Q1 | 103.33 Thousand USD | -50.5% |
| 2022 FY | 22.78 Thousand USD | -89.09% |
| 2022 Q4 | 22.78 Thousand USD | -54.98% |
| 2022 Q3 | 50.6 Thousand USD | -34.88% |
| 2022 Q2 | 77.7 Thousand USD | -24.8% |
| 2021 FY | 208.73 Thousand USD | 145.32% |
| 2021 Q4 | 208.73 Thousand USD | -9.24% |
| 2021 Q1 | 105.62 Thousand USD | 24.14% |
| 2021 Q3 | 229.98 Thousand USD | 61.44% |
| 2021 Q2 | 142.45 Thousand USD | 34.86% |
| 2020 Q1 | 100.11 Thousand USD | 120.86% |
| 2020 Q3 | 56.24 Thousand USD | -34.36% |
| 2020 Q4 | 85.08 Thousand USD | 51.29% |
| 2020 FY | 85.08 Thousand USD | 87.71% |
| 2020 Q2 | 85.68 Thousand USD | -14.41% |
| 2019 FY | 45.32 Thousand USD | -63.5% |
| 2019 Q3 | 106.74 Thousand USD | -28.91% |
| 2019 Q1 | 144.77 Thousand USD | 16.57% |
| 2019 Q2 | 150.16 Thousand USD | 3.72% |
| 2019 Q4 | 45.32 Thousand USD | -57.54% |
| 2018 Q2 | 142.97 Thousand USD | -12.91% |
| 2018 Q1 | 164.15 Thousand USD | -15.72% |
| 2018 Q4 | 124.19 Thousand USD | -39.0% |
| 2018 Q3 | 203.58 Thousand USD | 42.4% |
| 2018 FY | 124.19 Thousand USD | -36.24% |
| 2017 Q4 | 194.77 Thousand USD | 6.1% |
| 2017 FY | 194.77 Thousand USD | -16.71% |
| 2017 Q3 | 183.57 Thousand USD | -3.73% |
| 2017 Q2 | 190.69 Thousand USD | -53.64% |
| 2017 Q1 | 411.31 Thousand USD | 75.89% |
| 2016 Q1 | 137.15 Thousand USD | -5.96% |
| 2016 Q4 | 233.84 Thousand USD | 16.52% |
| 2016 FY | 233.84 Thousand USD | 60.34% |
| 2016 Q3 | 200.68 Thousand USD | -65.27% |
| 2016 Q2 | 577.77 Thousand USD | 321.25% |
| 2015 Q4 | 145.84 Thousand USD | -71.6% |
| 2015 Q2 | 225.95 Thousand USD | -42.81% |
| 2015 Q1 | 395.08 Thousand USD | -1.31% |
| 2015 FY | 145.84 Thousand USD | -63.57% |
| 2015 Q3 | 513.55 Thousand USD | 127.29% |
| 2014 Q4 | 400.3 Thousand USD | 140.92% |
| 2014 FY | 400.3 Thousand USD | 671.98% |
| 2014 Q1 | 441.22 Thousand USD | 750.87% |
| 2014 Q3 | 166.16 Thousand USD | -46.72% |
| 2014 Q2 | 311.84 Thousand USD | -29.32% |
| 2013 Q4 | 51.85 Thousand USD | 55.53% |
| 2013 Q2 | 53.98 Thousand USD | -60.09% |
| 2013 Q1 | 135.27 Thousand USD | -31.93% |
| 2013 FY | 51.85 Thousand USD | -73.91% |
| 2013 Q3 | 33.34 Thousand USD | -38.25% |
| 2012 Q4 | 198.72 Thousand USD | -94.62% |
| 2012 Q3 | 3.69 Million USD | 443.64% |
| 2012 Q2 | 679 Thousand USD | -28.65% |
| 2012 Q1 | 951.59 Thousand USD | -47.73% |
| 2012 FY | 198.72 Thousand USD | -89.08% |
| 2011 Q1 | 2.1 Million USD | -41.11% |
| 2011 Q2 | 1.77 Million USD | -15.6% |
| 2011 Q4 | 1.82 Million USD | 168.43% |
| 2011 Q3 | 678.25 Thousand USD | -61.75% |
| 2011 FY | 1.82 Million USD | -48.96% |
| 2010 FY | 3.56 Million USD | 405.29% |
| 2010 Q4 | 3.56 Million USD | -26.91% |
| 2010 Q3 | 4.88 Million USD | -12.98% |
| 2010 Q2 | 5.6 Million USD | -34.41% |
| 2010 Q1 | 8.55 Million USD | 1111.13% |
| 2009 Q2 | 1.92 Million USD | -32.77% |
| 2009 FY | 705.97 Thousand USD | -86.3% |
| 2009 Q1 | 2.87 Million USD | -44.29% |
| 2009 Q4 | 705.97 Thousand USD | -61.77% |
| 2009 Q3 | 1.84 Million USD | -4.31% |
| 2008 Q3 | 8.09 Million USD | -30.56% |
| 2008 Q4 | 5.15 Million USD | -36.34% |
| 2008 FY | 5.15 Million USD | -72.04% |
| 2008 Q1 | 15.23 Million USD | -17.34% |
| 2008 Q2 | 11.65 Million USD | -23.49% |
| 2007 Q4 | 18.42 Million USD | -14.23% |
| 2007 Q1 | 11.85 Million USD | 13.6% |
| 2007 FY | 18.42 Million USD | 76.61% |
| 2007 Q2 | 9.51 Million USD | -19.71% |
| 2007 Q3 | 21.48 Million USD | 125.76% |
| 2006 FY | 10.43 Million USD | -41.99% |
| 2006 Q3 | 13.4 Million USD | -17.68% |
| 2006 Q2 | 16.28 Million USD | -18.36% |
| 2006 Q1 | 19.94 Million USD | 10.85% |
| 2006 Q4 | 10.43 Million USD | -22.14% |
| 2005 Q4 | 17.98 Million USD | -13.75% |
| 2005 Q3 | 20.85 Million USD | -10.49% |
| 2005 Q1 | 26.27 Million USD | -99.91% |
| 2005 Q2 | 23.3 Million USD | -11.32% |
| 2005 FY | 17.98 Million USD | -39.86% |
| 2004 Q2 | 22.89 Million USD | -2.75% |
| 2004 FY | 29.91 Million USD | 1272.68% |
| 2004 Q1 | 23.53 Million USD | 260.57% |
| 2004 Q3 | 20.74 Million USD | -9.36% |
| 2004 Q4 | 28.35 Billion USD | 136571.32% |
| 2003 Q3 | 5.21 Million USD | 139.12% |
| 2003 Q2 | 2.17 Million USD | 99.57% |
| 2003 Q4 | 6.52 Million USD | 25.28% |
| 2003 FY | 2.17 Million USD | -26.9% |
| 2003 Q1 | 1.09 Million USD | -22.02% |
| 2002 Q1 | 3.87 Million USD | -12.3% |
| 2002 FY | 2.98 Million USD | -46.2% |
| 2002 Q4 | 1.4 Million USD | -43.54% |
| 2002 Q3 | 2.48 Million USD | -16.8% |
| 2002 Q2 | 2.98 Million USD | -23.01% |
| 2001 Q3 | 6.06 Million USD | 9.54% |
| 2001 Q1 | 6.02 Million USD | -11.8% |
| 2001 FY | 5.54 Million USD | 58.84% |
| 2001 Q2 | 5.54 Million USD | -8.0% |
| 2001 Q4 | 4.41 Million USD | -27.25% |
| 2000 Q1 | 1.14 Million USD | 72.94% |
| 2000 FY | 3.48 Million USD | 125.18% |
| 2000 Q4 | 6.82 Million USD | 98.18% |
| 2000 Q3 | 3.44 Million USD | -1.22% |
| 2000 Q2 | 3.48 Million USD | 205.8% |
| 1999 Q3 | 856.88 Thousand USD | -44.72% |
| 1999 Q1 | 2.05 Million USD | 105.0% |
| 1999 FY | 1.54 Million USD | -46.12% |
| 1999 Q4 | 659.54 Thousand USD | -23.03% |
| 1999 Q2 | 1.55 Million USD | -24.39% |
| 1998 Q1 | 4.1 Million USD | -25.45% |
| 1998 Q4 | 1 Million USD | -44.44% |
| 1998 Q3 | 1.8 Million USD | -37.39% |
| 1998 FY | 2.87 Million USD | -65.5% |
| 1998 Q2 | 2.87 Million USD | -29.88% |
| 1997 Q4 | 5.5 Million USD | -19.12% |
| 1997 FY | 8.33 Million USD | 66.2% |
| 1997 Q1 | 5.4 Million USD | 50.0% |
| 1997 Q2 | 8.33 Million USD | 54.32% |
| 1997 Q3 | 6.8 Million USD | -18.4% |
| 1996 Q3 | 3.8 Million USD | -24.21% |
| 1996 Q4 | 3.6 Million USD | -5.26% |
| 1996 Q2 | 5.01 Million USD | -10.47% |
| 1996 Q1 | 5.6 Million USD | -11.11% |
| 1996 FY | 5.01 Million USD | 2.32% |
| 1995 Q3 | 4 Million USD | -18.37% |
| 1995 Q4 | 6.3 Million USD | 57.5% |
| 1995 FY | 4.9 Million USD | -52.88% |
| 1995 Q1 | 5.9 Million USD | -18.06% |
| 1995 Q2 | 4.9 Million USD | -16.95% |
| 1994 Q4 | 7.2 Million USD | -19.1% |
| 1994 Q1 | 11.9 Million USD | -8.53% |
| 1994 Q2 | 10.4 Million USD | -12.61% |
| 1994 Q3 | 8.9 Million USD | -14.42% |
| 1994 FY | 10.4 Million USD | 447.37% |
| 1993 Q3 | 1.15 Million USD | -39.47% |
| 1993 Q1 | 2.7 Million USD | -4.59% |
| 1993 Q4 | 13.01 Million USD | 1031.3% |
| 1993 FY | 1.9 Million USD | -38.71% |
| 1993 Q2 | 1.9 Million USD | -29.63% |
| 1992 Q2 | 3.1 Million USD | 1.97% |
| 1992 Q3 | 2.11 Million USD | -31.94% |
| 1992 FY | 3.1 Million USD | -6.06% |
| 1992 Q4 | 2.83 Million USD | 34.12% |
| 1992 Q1 | 3.04 Million USD | 71.75% |
| 1991 Q3 | 2.54 Million USD | -23.03% |
| 1991 Q4 | 1.77 Million USD | -30.31% |
| 1991 FY | 3.3 Million USD | -15.38% |
| 1991 Q1 | 2.11 Million USD | -23.27% |
| 1991 Q2 | 3.3 Million USD | 56.4% |
| 1990 Q3 | 3.4 Million USD | -12.82% |
| 1990 FY | 3.9 Million USD | 178.57% |
| 1990 Q1 | 4.54 Million USD | -11.15% |
| 1990 Q2 | 3.9 Million USD | -14.1% |
| 1990 Q4 | 2.75 Million USD | -19.12% |
| 1989 Q3 | 5.73 Million USD | 309.29% |
| 1989 Q2 | 1.4 Million USD | 0.0% |
| 1989 Q4 | 5.11 Million USD | -10.82% |
| 1989 FY | 1.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -886.19% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 98.837% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.784% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 95.874% |
| Rebus Holdings, Inc. | 5000.00 USD | -355.62% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.983% |
| Qrons Inc. | 420.00 USD | -5324.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 97.044% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.918% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 95.259% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.809% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.941% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.684% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 70.164% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.979% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 98.409% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 68.519% |
| Mesoblast Limited | 667.9 Million USD | 99.997% |
| Marizyme, Inc. | 22.01 Million USD | 99.897% |
| Genus plc | 1.02 Billion USD | 99.998% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 98.323% |
| Pharming Group N.V. | 462.85 Million USD | 99.995% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.312% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 95.435% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 96.367% |
| ContraFect Corporation | 20.67 Million USD | 99.89% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 94.164% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 94.039% |
| IMV Inc. | 31.33 Million USD | 99.927% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.451% |
| MultiCell Technologies, Inc. | 126.22 USD | -17948.645% |
| ONE Bio Corp. | 70.08 Million USD | 99.967% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 97.576% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.982% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 94.723% |
| Q BioMed Inc. | 3.51 Million USD | 99.352% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.935% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 91.281% |
| Biomind Labs Inc. | 73.81 Thousand USD | 69.139% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.995% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 98.428% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.924% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.17% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 96.686% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.125% |
| GB Sciences, Inc. | 103.44 Thousand USD | 77.977% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.071% |
| HST Global, Inc. | 1526.00 USD | -1392.857% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 97.694% |
| Halberd Corporation | 10.13 Thousand USD | -124.864% |
| Enzolytics Inc. | 361.7 Million USD | 99.994% |
| Agentix Corp. | 261.39 Thousand USD | 91.285% |
| Resverlogix Corp. | 8.11 Million USD | 99.719% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 98.787% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.952% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 96.439% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.745% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.691% |
| Zenith Capital Corp. | 7410.00 USD | -207.436% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.999% |
| Ember Therapeutics, Inc. | 184.00 USD | -12280.978% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 92.921% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 91.284% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 97.545% |
| Kadimastem Ltd | 2.3 Million USD | 99.011% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.247% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.957% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.844% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 60.099% |
| LadRx Corporation | 2.3 Million USD | 99.013% |
| Cell Source, Inc. | 195.17 Thousand USD | 88.328% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 93.558% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 93.558% |
| NovAccess Global Inc. | 62.24 Thousand USD | 63.403% |
| Affymax, Inc. | 7.44 Million USD | 99.694% |
| Itoco Inc. | 1.4 Million USD | 98.373% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 76.185% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 78.508% |
| Mobile Lads Corp. | 52.00 USD | -43709.615% |
| CytoDyn Inc. | 11.13 Million USD | 99.795% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 84.066% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -27.411% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 94.09% |
| SYBLEU INC | 330.46 Thousand USD | 93.106% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 94.436% |
| International Stem Cell Corporation | 5.39 Million USD | 99.577% |
| Bioxytran, Inc. | 137.63 Thousand USD | 83.449% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.848% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.863% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 71.163% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 97.365% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.697% |
| Neutra Corp. | 2851.00 USD | -699.053% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.93% |
| PureTech Health plc | 693.97 Million USD | 99.997% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.718% |
| IXICO plc | 15.84 Million USD | 99.856% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.725% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.978% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.993% |